A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estroge

Trial Details

NCT ID

NCT06966700

Phase

PHASE3

Sponsor

Merck Sharp & Dohme LLC

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

Sacituzumab tirumotecan
Pembrolizumab
Rescue Medication
Carboplatin
Paclitaxel
Doxorubicin

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Phoenix, Arizona, United States|33.44838,-112.07404
Tucson, Arizona, United States|32.22174,-110.92648
Burbank, California, United States|34.18084,-118.30897
Fullerton, California, United States|33.87029,-117.92534

Key Eligibility Criteria

The main inclusion criteria include but are not limited to the following:
Has previously untreated high-risk, early-stage, non-metastatic (M0) breast cancer (BC), defined as any of the following combined primary tumor (T)…
cT1c, N1-N2
cT2, N0-N2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →